-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to information made public by the Drug Review Center (CDE) of the State Drug Administration of China, BEBT-260, a new class of chK1 inhibitors injected by Bibert Pharmaceuticals, has obtained an implied license for clinical trials to treat advanced solid tumors that recur after at least two systemic treatments.
note that no ChK1 inhibitors have yet been approved for the global market.
BEBT-260 is a selective and powerful cell cycle ChK1 inhibitor with an innovative chemical structure and global ownership of Bibert Pharmaceuticals.
cell cycle checkpoint kinase 1 (ChK1, checkpoint kinase 1) is a member of the serine/suline protein kinase family and is the core protein of the cell cycle detection point in the DNA damage response (DNA damage response, DDR).
studies have shown that Chk1 protein kinase has the function of promoting tumor cell growth, its lack of tumor cells can be more sensitive to radiotherapy or chemotherapy, and its inhibitors in combination with other molecularly targeted drugs have a "synthetic lethal" effect.
chk1 is also seen as one of the targets of cancer treatment.
, BEBT-260 enhances the activity of chemotherapy drugs in a variety of tumor cells.
beBT-260 showed significant anti-tumor activity when used alone or in combination with chemotherapy drugs.
, Bibert Pharmaceuticals intends to use the product alone or in combination with chemotherapy drugs for the treatment of various solid tumors, especially 2003-carrying TP53 mutations.
, chK1 inhibitors have not yet been approved for the global market.
are also less clinically developing ChK1 inhibitors, which are known to be being developed by companies such as Lilly, Roche and Sierra Oncology.
congratulations on the approval of Bibbett Pharmaceuticals BEBT-260 clinically, and looks forward to the smooth progress of the follow-up research of this product to bring innovative therapies to patients at an early time.
.